CDH17 recombinant proteins and antibodies

Cadherin-17 (CDH17), also known as intestinal cadherin (LI-cadherin) or human peptide transporter-1 (HPT-1), is a structurally unique member of the cadherin superfamily. CDH17 was originally discovered in the rat liver and intestine, so it is also called intestinal cadherin. In the human body, the distribution of CDH17 is limited to the duodenum, jejunum, ileum, colon, and part of the pancreatic duct. It is rarely detected in other tissues such as the liver, kidney, and heart of healthy adults. In the intestinal epithelium, CDH17 is mainly located on the lateral and basal membranes of cells. In tumor cells, similar to specific targets such as Claudin18.2, CDH17 is expressed on the surface of tumor cells due to the lack of polarity.

Studies have found that CDH17 is expressed to varying degrees in gastric cancer, colorectal cancer, bile duct cancer, pancreatic cancer, and hepatocellular carcinoma. Moreover, CDH17 is associated with the prognosis of various solid tumors, and its high expression in patients with gastric cancer and colorectal cancer is associated with shorter survival and disease-free progression. More about the mechanism of action of CDH17 >>

DIMA BIOTECH now provides a full range of products and services for CDH17 targets. Products include active proteins, reference antibodies, and flow cytometry-validated monoclonal antibodies; services include customized services for antibodies of various genera, antibody humanization and affinity maturation services. In addition, to accelerate the development of CDH17 biotherapy, DIMA BIOTECH has also prepared a CDH17 target single B cell seed library, and lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened dozens of CDH17 lead molecules, several of which have verified human-monkey protein cross-reactivity, and customers can get the molecules for functional evaluation and verification the next day; for some molecules, we are also conducting ADC endocytosis activity and killing verification, and please inquire for specific data.